Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta Therapeutics (SRPT) sold over $174 million of its Arrowhead Pharmaceuticals equity to fund a $100 million milestone payment to Arrowhead, triggered by the SRP-1003 (DM1) Phase I/II study's progress. This transaction, which led to a 9% rise in SRPT shares despite an 83.2% YTD decline, highlights Sarepta's financial maneuvering amidst significant challenges, including safety issues with its flagship gene therapy Elevidys and a strategic shift towards its acquired siRNA pipeline, reinforced by a recent restructuring. Arrowhead will also repurchase $50 million of its own stock from Sarepta.

Analysis

Sarepta Therapeutics (SRPT) is executing a critical financial maneuver by liquidating at least $174 million of its equity in Arrowhead Pharmaceuticals to cover a $100 million milestone payment owed to Arrowhead. This payment was triggered by the advancement of SRP-1003, an investigational RNAi therapeutic for myotonic dystrophy type 1, which successfully met enrollment and safety criteria in its Phase I/II study. While SRPT's shares rallied 9% on the news, the transaction occurs amidst severe corporate distress, highlighted by an 83.2% year-to-date stock decline. This plunge is primarily attributed to significant safety issues with its key revenue driver, the gene therapy Elevidys, which has been linked to patient deaths and contributes over half of total revenues. The event underscores Sarepta's strategic pivot, reinforced by a major restructuring plan involving a 36% workforce reduction, away from its troubled gene therapy platform and towards its pipeline of RNAi therapeutics acquired from Arrowhead. Arrowhead's participation, via a $50 million stock buyback from Sarepta to prefund half the milestone, signals confidence in its own platform's clinical progress.

Key Decisions for Investors

• Investors should view Sarepta's recent stock rally with caution, as it is driven by a necessary financing transaction and early pipeline progress rather than a resolution of the fundamental safety and revenue concentration risks tied to its flagship product, Elevidys.
• The strategic shift towards the siRNA pipeline from Arrowhead is now central to Sarepta's potential recovery; therefore, closely monitoring clinical data from the SRP-1003 and FSHD programs expected in late 2025 and later this year is critical for assessing long-term viability.
• Given that over half of Sarepta's revenue depends on Elevidys, any further negative safety developments or commercial headwinds for the therapy could severely impact the company's financial stability, despite the ongoing restructuring.
• For investors in Arrowhead Pharmaceuticals, the receipt of the milestone payment and the concurrent stock buyback serve as positive validation of its licensed RNAi platform, suggesting further upside as partnered programs advance.